1/30/2023  5:31:43 PM Chg. +0.0300 Volume Bid5:40:00 PM Ask5:40:00 PM Market Capitalization Dividend Y. P/E Ratio
0.4300CHF +7.50% 344,858
Turnover: 143,183.8360
0.4000Bid Size: 15,500 0.4400Ask Size: 10,000 4.82 mill.CHF 0.00% -

Business description

Spexis AG is a research-driven clinical-stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance leveraging the company's leading macrocyclic peptide technology platform. Spexis AG is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer and exploring its potential in other cancer indications. In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. The company's lead OMPTA program is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Spexis AG is based in Allschwil near Basel and is listed on the SIX Swiss Exchange.
 

Management board & Supervisory board

CEO
Gökhan Batur
Management board
Hernan Levett, Dr. Daniel Obrecht, Frank Weber, M.D., Franziska Müller
Supervisory board
Dr. Kuno Sommer, Bernard Bollag, Dr. Andreas Wallnöfer, Dr. Silvio Inderbitzin, Hugh O’Dowd
 

Company data

Name: Spexis AG
Address: Hegenheimermattweg 125,CH-4123 Allschwil
Phone: +41-61-567-1600
Fax: -
E-mail: info@polyphor.com
Internet: https://www.polyphor.com/
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: -
IPO date: 5/15/2018

Investor relations

Name: Hernan Levett
IR phone: +41-61-567-1624
IR Fax: -
IR e-mail: IR@polyphor.com

Main Shareholders

Freefloat
 
74.52%
Ingro Finanz AG
 
11.09%
Varuma AG
 
8.40%
CS Inv. Funds 2-Credit Suisse
 
5.99%